Navigation Links
Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Date:5/20/2008

LOS ANGELES, May 20 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE). Ross Silver, Director of Research of Vista Partners stated, "Alseres' recombinant-protein-based drug named Cethrin has shown highly encouraging clinical and preclinical data to date. Cethrin would serve a multi-billion dollar market if approved. In addition to Cethrin, Alseres has a molecular imaging program in Phase III clinical trials, a program we believe will likely be partnered within the next 12 months. Alseres is a highly attractive investment at its current valuation." To download a free copy of the report, please visit the Vista Partners website, http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Alseres Pharmaceuticals, Inc.:

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initi
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Initiative expands to include cost-effective, su..., and healthcare professionals in developing world...) November 25, 2009 -- Elluminate, Inc. , the lea...lutions that support 21st century teaching, learn...Fire and Ice initiative was awarded iNACOL,s fir...
(Date:11/25/2009)....25/PRNewswire/--dazzlesmile,llc www.dazzlesmile.c...ience.com havefileda67-pagefederallawsuitagainstEp...eWillms,FarendServicesLimited,andAtLastFulfillment...rictCourtfortheDistrictofUtah,allegesmassivenation...ndedteethwhiteningproducts,violationsoftheRacketee...
(Date:11/25/2009)...able in French and Spanish . , , Resear...ed an early diagnosis of certain ocular diseases t...ular degeneration and keratitis, by applying an ex...ever before been used for this purpose. , Scient... in subjects affected by one of these two patholog...
(Date:11/25/2009)... Physicians at UT Southwestern Medical Center soon...prove breathing in patients with upper spinal-cord...eathing independently. , UT Southwestern Univer...tes in Texas and one of 25 in the country currentl... Diaphragm Pacing System. , The device is design...
(Date:11/25/2009)... Citing support for recent enforcement actions ag...al Association of Chain Drug Stores (NACDS) submit...FDA). The letter expresses the Association’...c and foreign, that are engaged in a pattern of il...nsing of prescription medications. , ...
Breaking Medicine News(10 mins):Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2Health News:NACDS Supports FDA Enforcement Against Rogue Internet Pharmacy Websites 2
...rch 24 Health Fitness,Corporation (OTC Bulletin B...ctors has authorized a plan to repurchase up to $2...res. Under the plan, the company may,repurchase sh... and other pertinent rules and regulations. The sh...
... Day In A SpaCapsule, Could Change The Outcome Of ...tion, MIAMI, March 24 With the Presidential cand... McCain, Hillary Clinton and,Barack Obama,s stress.... This can cause lack of sleep and lack of food,wh...
...ial published early online today, JAMA Editor-in-C...A Editorial Counsel Joseph P. Thornton, J.D., writ... involving JAMA and the Archives of Internal Medic...subpoenas last year to obtain confidential informa...
...S, Mich., March 24 During National Root,Canal Awa...ies of articles,is available for publication court...opics include healthy dental tips for aging, facts...overall health, Oral health is not only important...
...on Newsstands March 25, MILWAUKEE, March 24 As i...creases, Taste of Home, the largest cooking magazi... magazine that gives readers,what they need for a ...king makes it easier to manage medical conditions ...
...24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,...), a leading China-based,medical device company th...,vitro diagnostic ("IVD") products and high intens...tomatic ECLIA,analyzers and 15 reagents., Under t...
Other Medicine News:Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Stress On The Campaign Trail, One Issue All The Candidates Agree On 2Health News:Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy 2Health News:Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy 3Health News:Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy 4Health News:Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy 5Health News:Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy 6Health News:Taste of Home Magazine Launches Healthy Cooking 2Health News:China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents 2
(Date:11/24/2009)..., IRVINE,Calif.,Nov.24/PRNewswire-FirstCall/-...yinvasivetreatmentsforaorticdisorders,announcedtod...eedingsin,thepatentinfringementlawsuitbroughtagain...UnitedStatesDistrictCourtinIndianapolis,Indiana. ,...twhiletheUnitedStatesPatentandTrademarkOffice(USPT...
(Date:11/24/2009)..., FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/...theCompanyfileditsPlanofReorganizationandDisclosur...sBankruptcyCourtfortheDistrictofDelaware.Ahearingt...lyscheduledforDecember8,2009,withthehearingontheco..., ThePlancallsfortheCompanytopayallclaimsinfull.Th...
(Date:11/24/2009)..., WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewsw...U.S.FoodandDrugAdministration(FDA)hasacceptedforre...Aricept®(donepezilHClextendedrelease)tabletsf...(AD).Thisnewhigherdoseformulationcontains23mgofdon...adeliverysystemthatallowsforgradualreleaseofthedru...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 1Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 2Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 1Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 2Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 1Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 2
...ll/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: ...n,endocrine therapy and oncology, today reported t...ruitment for its Phase 2 trial in ovarian cancer,w...one (LHRH) agonist,linked to doxorubicin. The deci...ent was taken following recent first stage data re...
...gual lozenge) developed to be the first sleep aid...hen patients awaken and have difficulty re...ranscept Pharmaceuticals,Inc., a privately-held sp...at it has submitted a New Drug Application (NDA) t...its lead product candidate, Intermezzo(R),(zolpide...
Other Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6
...tem includes a cruciate sparing version which prov...h resurfacing and inset patellas. Precision machin...and fit with tibial articular surface and patella ...ns provide easy intraoperative change of sizes. Ex...
...re than a decade of in-vivo research, the 3DKnee d...nematics through fluoroscopic review, tibial plate....,As a result of this exhaustive analysis of path...al knees, the 3DKnee implant provides an articulat...
...eg; PS knee offers a femoral option and tibial ins... that engages at 60 degrees of flexion to induce a...for 130 degrees of flexion. Femoral component come...lare. The constrained tibial insert in conjunction...
Foundation® Knee CR System
Medicine Products: